Detect

Guilford, Connecticut

Classification

Private

About

About

Detect, Inc. is a biotechnology company that specializes in developing and providing rapid, accurate, and affordable diagnostic testing solutions. The company focuses on leveraging cutting-edge technology to enhance early detection and monitoring of diseases, aiming to improve healthcare outcomes and accessibility. Product/Service Line Breakdown: 1. Rapid Diagnostic Tests: Highly sensitive and specific tests designed for quick detection of various diseases, providing results within minutes. 2. At-Home Testing Kits: User-friendly kits that enable individuals to conduct diagnostic tests from the comfort of their homes, ensuring privacy and convenience. 3. Clinical Diagnostic Solutions: Advanced diagnostic tools and platforms tailored for healthcare providers to enhance diagnostic accuracy and patient care in clinical settings. 4. Data Analytics and Reporting: Comprehensive software solutions that analyze test results and provide actionable insights for better disease management and monitoring. 5. Research and Development Services: Collaborative R&D initiatives aimed at developing new diagnostic technologies and improving existing ones to meet emerging healthcare challenges.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private